Biomerica’s Fortel Ulcer Test Approved in UAE for Home Use

The United Arab Emirates (UAE) Ministry of Health and Prevention has approved Biomerica Inc.’s Fortel Ulcer Test for home use.

The Fortel Ulcer Test is a 10-minute rapid diagnostic assay that detects antibodies to Helicobacter pylori (H. pylori), a bacterium responsible for peptic ulcers, dyspepsia, and a significant portion of gastric cancer cases. With this new regulatory approval, individuals in the UAE can now self-administer the test in the comfort and privacy of their own homes.

H. pylori affects approximately 41% of the UAE population, with higher prevalence among certain age and ethnic groups. If left untreated, up to 20% of infected individuals may develop serious complications such as peptic ulcers, chronic digestive pain, or gastric malignancies. Up to 80% of gastric cancer cases are linked to H. pylori infection, making it one of the most concerning infectious cancer risk factors. In recognition of its global impact, the World Health Organization (WHO) has classified H. pylori as a Class 1 carcinogen and listed it among the top antibiotic-resistant bacterial threats to human health.

With home-use approval now in place, Biomerica is partnering with UAE-based distributors and healthcare providers to make the Fortel Ulcer Test available at pharmacies, clinics, and online platforms. This approval strengthens Biomerica’s growing presence in the Middle East, building on the successful regional launch of the EZ Detect Colon Disease Test and other diagnostics designed for early detection and better patient outcomes.

“With this home-use approval, we’re giving people direct access to a reliable tool for early detection of a dangerous infection that could result in serious complications,” Biomerica CEO Zack Irani said. “This can help drive earlier and more effective medical treatment and potentially save lives.”

Biomerica remains focused on delivering affordable, innovative diagnostic tools that improve patient outcomes through early disease detection. The Fortel Ulcer Test exemplifies an easy to implement solution in the fight against H. pylori-related illnesses and reflects the company’s mission to improve global health with accessible and effective diagnostics.

Biomerica Inc. is a global biomedical technology company that develops, patents, manufactures, and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians’ offices) and in hospital/clinical laboratories to detect and/or treat medical conditions and diseases. The company’s products primarily focus on gastrointestinal and inflammatory diseases.